【摘要】 目的观察大骨节Ⅰ号方丸剂治疗大骨节病的临床疗效。方法选择大骨节病患者187例,随机分为3组:治疗组70例、对照组A 67例、对照组B 50例,分别给予口服大骨节Ⅰ号方丸剂、布洛芬缓释胶囊、维生素C片。以上各组均连续服药3个月后观察疗效,并随访观察半年。以国家"大骨节病治疗效果判定标准(Ws/T79-1996)"和国际通用的"视觉疼痛判定标准(VAS)"来观察治疗效果。结果 3个月疗程结束后,治疗组、对照组A的临床疗效分别为91.43%和89.55%,差异无统计学意义(P>0.05),患者症状和体征改善,关节功能改善。对照组B的疗效仅为22%,和治疗组相比,差异有统计学意义,(P<0.05)。停药半年的随访观察中,治疗组、对照组A比较的临床疗效差异不显著(P>0.05);但治疗组、对照组A与对照组B比较,差异有统计学意义(P<0.05);结论大骨节Ⅰ号方丸剂治疗大骨节病的效果显著,未出现不良反应。更多还原

【Abstract】 Objective To evaluate the clinical efficacy of Tibet medicine namely DaGuJie I Formulation on Kashin-Beck disease.Methods 187 cases of Kashin-Beck disease were randomly divided into the treatment group,with patients treated by DaGuJie I Formulation,the control group A,with 67 patients treated by Ibuprofen capsules and control group B with 50 patients treated by vitamin C.Its efficacy was observed by continuously taking the med- icine 3 months,and six months follow-up observation for the long-term effect.The clinical efficacy was assessed ac- cording to "Kashin-Beck disease Treatment Criteria of China"(Ws/T79-1996)and international accepted Pain Visual Criteria(VAS).Result After three months treatment,the clinical effect of treatment group,control group A and control group B was 91.43%,89.55%and 22%respectively.There was no statistical significance(P>0.05) be- tween treatment group and control group A;but it showed statistical significance(P<0.05) between treatment group and control group B or control group A and control B.The clinical efficacy of treatment group and the control group A showed statistical significance compared with control group B after six months follow-up observation(P< 0.05).Conclusion DaGuJie I Formulation significantly improved the clinical symptom of patients with Kashin- Beck disease,without toxic side effects.更多还原